The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer
- PMID: 18300765
- DOI: 10.1097/CCO.0b013e3282f54cf2
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer
Abstract
Purpose of review: Skeletal metastases are a frequent site of involvement for patients with metastatic nonsmall cell lung cancer. Skeletal metastases may result in skeletal-related events. These complications typically result in significant morbidity for patients and substantially increase the economic costs associated with the treatment of patients with skeletal metastases. The management of skeletal metastases in patients with nonsmall cell lung cancer is evolving as improved treatments and monitoring become available.
Recent findings: In recent years, bisphosphonates such as zoledronic acid have shown efficacy in preventing and delaying skeletal-related events in patients with a variety of solid tumors, including nonsmall cell lung cancer. Biochemical markers of bone turnover such as bone-specific alkaline phosphatase and N-terminal telopeptide of collagen type I have shown some utility in predicting which patients are at greatest risk of developing skeletal-related events. These biochemical markers may play a role in directing treatment of skeletal metastases with either bisphosphonates or newer targeted therapies such as denosumab.
Summary: The management of skeletal metastases from nonsmall cell lung cancer is evolving as biochemical markers may be used to guide the treatment of these patients. Newer targeted therapies are also in development and may be used in the treatment of patients with skeletal metastases.
Similar articles
-
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.J Natl Cancer Inst. 2005 Jan 5;97(1):59-69. doi: 10.1093/jnci/dji002. J Natl Cancer Inst. 2005. PMID: 15632381
-
Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.Clin Lung Cancer. 2011 Nov;12(6):341-9. doi: 10.1016/j.cllc.2011.03.032. Epub 2011 May 17. Clin Lung Cancer. 2011. PMID: 21703936 Review.
-
Can bone markers guide more effective treatment of bone metastases from breast cancer?Breast Cancer Res Treat. 2006 May;97(1):81-90. doi: 10.1007/s10549-005-9094-7. Epub 2005 Dec 1. Breast Cancer Res Treat. 2006. PMID: 16319976 Review.
-
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.Semin Oncol. 2007 Dec;34(6 Suppl 4):S17-23. doi: 10.1053/j.seminoncol.2007.10.006. Semin Oncol. 2007. PMID: 18068486 Review.
-
Biochemical markers and skeletal metastases.Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S138-47. doi: 10.1097/01.blo.0000092979.12414.54. Clin Orthop Relat Res. 2003. PMID: 14600604 Review.
Cited by
-
Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth.Int J Mol Sci. 2021 Mar 13;22(6):2911. doi: 10.3390/ijms22062911. Int J Mol Sci. 2021. PMID: 33805598 Free PMC article. Review.
-
Fracture risk assessment and clinical decision making for patients with metastatic bone disease.J Orthop Res. 2020 Jun;38(6):1175-1190. doi: 10.1002/jor.24660. Epub 2020 Mar 23. J Orthop Res. 2020. PMID: 32162711 Free PMC article. Review.
-
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases.PLoS One. 2016 Dec 8;11(12):e0167923. doi: 10.1371/journal.pone.0167923. eCollection 2016. PLoS One. 2016. PMID: 27930702 Free PMC article.
-
Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort.J Cancer. 2016 Oct 23;7(14):2110-2116. doi: 10.7150/jca.16211. eCollection 2016. J Cancer. 2016. PMID: 27877227 Free PMC article.
-
Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases.Oncotarget. 2016 Mar 15;7(11):12612-22. doi: 10.18632/oncotarget.7278. Oncotarget. 2016. PMID: 26871471 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
